Multiple Sclerosis Journal

Article	Citations
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	117
Sars-CoV2 infection in pregnant women with multiple sclerosis	90
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	86
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No	72
Time to move past typical syndromes in the diagnosis of multiple sclerosis	62
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	60
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	52
Therapy challenges for NMOSD in a patient with HIV	51
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	47
Decentralised clinical trials in multiple sclerosis research	43
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	43
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	42
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	42
Impact of cancer on multiple sclerosis–related healthcare and disease-modifying drug use: A multinational cohort study	42
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial	42
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab	41
Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study	40
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	38
Characterizing financial toxicity among people living with neuromyelitis optica spectrum disorder	37
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088.	36
Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab	35
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	34
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	34
Double-negative neuromyelitis optica spectrum disorder	33
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	32

Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities	32
Optic nerve assessments in MS diagnosis are worth the added implementation complexity: Yes	31
Immunosenescence in multiple sclerosis: New insights and clinical implications	31
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis	31
High-risk populations should be screened for MS—Commentary	30
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study	30
Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage	30
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry	29
Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack	29
A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma	28
Metabolic and lipid alterations in multiple sclerosis linked to disease severity	28
Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation	28
Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis	26
White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study	26
Anti-CD20 therapy in pregnancy: Balancing risks and benefits	26
Low transfer of cladribine into human milk	26
The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics	26
Aspergillus myelitis : Breaking the mold to make a diagnosis	25
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society	25
The value of patient-reported outcome measures for multiple sclerosis	25
Pseudocystic demyelination in multiple sclerosis	24
Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial	24
To halt disease progression rehabilitation in MS should start early: Yes	23
Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients	22
The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022	22
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis	22
Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis	22
Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder	21
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France	21
EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold	21
High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate	21
Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort	21
Biological aging in multiple sclerosis	21
Mobile health interventions in multiple sclerosis: A systematic review	21
ECTRIMS 2024 Lecture: Unraveling the spectrum of the antibody-mediated demyelinating diseases: Emerging insights	21
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis	20
The MoXFo initiative – adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research	20
Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis	20
Response to the letter: Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model	20
What is a clinically isolated syndrome in the 21st century?	20
Ofatumumab-associated colitis: A case report	20
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial	19
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study	19
Depression is a core symptom of multiple sclerosis: Yes	19
Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model	19
Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis	18
Are neurofilament light chain levels ready for routine clinical use? – Commentary	18
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community	18
Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome	18
Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? No	18

The effects of gamma-tACS on cognitive impairment in multiple sclerosis: A randomized, double-blind, sham-controlled, pilot study	18
Filtered-phase imaging versus susceptibility-weighted imaging for paramagnetic rim lesion detection in multiple sclerosis: A head-to-head comparison	18
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort	18
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor	18
Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: A secondary data analysis	17
Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration	17
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis	17
Novel MRI metrics: Is targeting brain atrophy a practical treatment goal? Yes	17
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis	17
Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis	16
Telomere length as a biomarker in multiple sclerosis	16
Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals	16
Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021	16
ACTRIMS Forum 2026 - Author Index	16
Navigating the uncharted—Progressive multifocal leukoencephalopathy in a child with NMOSD treated with rituximab	16
Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model	16
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy	16
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations	16
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis	16
Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis	16
Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach	15
Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort	15
Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden	15
Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis	15
New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series	15
Exercise as a Therapeutic Intervention in Multiple Sclerosis	15
A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort stu	15
Baló’s concentric sclerosis successfully treated with alemtuzumab: Long-term follow-up	15
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study	15
Towards a phenotypic understanding of multiple sclerosis depression	15
Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis	14
Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States	14
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement	14
Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort	14
ACTRIMS Forum 2023 - Poster Presentations	14
Machine learning classification of multiple sclerosis in children using optical coherence tomography	14
The revised 2024 McDonald criteria can solve the misdiagnosis problem in multiple sclerosis: Commentary	14
Exosomal profiling should be used to monitor disease activity in MS patients: Commentary	14
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study	14
Addressing me in the context of my disease: Why it is so complicated	14
All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes	13
Differential vulnerability of thalamic nuclei in multiple sclerosis	13
Characteristics of multiple sclerosis and demyelinating disease in an Asian American population	13
A taxonomic approach to cognitive diagnostics is viable and achievable in MS	13
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis	13
AI-enabled Living Labs: Accelerating innovation in multiple sclerosis care and research	13
Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO	13
External validation of a clinical prediction model in multiple sclerosis	13
ACTRIMS Forum 2023 Invited Program	13
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice	12
Cognitive reserve in multiple sclerosis: The role of depression and fatigue	12
ACTRIMS Forum 2025 Author Index	12
Response to letter to the editor: ‘Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis’	12
Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study	12
The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives	12
Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics - Yes	12
Copy number variation at the complement C4 locus is associated with risk for multiple sclerosis	12
Myelin oligodendrocyte glycoprotein antibody-associated disease and relapse risk: Effects of smoking and vascular risk factors	12
The Barancik award lecture: Multi-disciplinary research will be the key to stop, restore, and end MS	12
Acute retinal necrosis associated with dimethyl fumarate	12
Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis	12
Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study	12
Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort	12
From “invisible” to “audible”: Features extracted during simple speech tasks classify patient-reported fatigue in multiple sclerosis	12
Assessing the association between mortality and clinical follow-up visits in multiple sclerosis	12
Response to letter to the editor “Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs”	12
ECTRIMS 2024 – Oral Presentations	12
Spinal cord imaging in multiple sclerosis: A vital component we can no longer overlook	12
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clini	12
Association between education level and disability progression in patients with multiple sclerosis in France	11
Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorder	11
Clinical commentary to “the cascade sign in aquaporin-4-IgG positive (AQP4-IgG+) NMOSD”	11
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial	11
MS becomes a treatable disease: 30 years later	11
Unveiling Misdiagnosis: Rethinking Seronegative NMOSD	11
Homonymous hemi-macular atrophy in multiple sclerosis	11
Paramagnetic rim lesion formation is predicted by the initial gadolinium-enhancing lesion diameter	11
Neurofilament light biomarkers in MS: Effects of extended natalizumab dosing	11
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions	11
Choroid plexus enlargement correlates with demyelinating lesions and thalamic atrophy in radiologically isolated syndrome	11

Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC)	11
Prevalence of neuromyelitis optica spectrum disorder in the United States	11
The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research	11
Persistent gadolinium enhancement: An emerging MRI feature in NMOSD?	11
Toward a global research agenda for preventing multiple sclerosis	11
Exosomal profiling should be used to monitor disease activity in MS patients: No	11
The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis	11
Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis	10
Quantifying observable movement reserve in multiple sclerosis via upper diurnal activity quantiles	10
Early corticosteroids predict visual whereas MRI lesion extent predicts retinal atrophy outcomes in MOG antibody–associated optic neuritis	10
Influence of OSCAR-IB criteria on test–retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis	10
Unemployment, work hour reduction, and income loss: An international, multicentered, cross-sectional study of neuromyelitis optica spectrum disorder	10
ACTRIMS Forum 2023 Author Index	10
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data	10
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study	10
Employment status, productivity loss, and associated factors among people with multiple sclerosis	10
Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty	10
Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis – Results of the randomised controlled POWER@MS1 trial	10
Dysarthria assessment in multiple sclerosis patients	10
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study	10
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial	10
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society	10
Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions	10
Treating comorbidities in multiple sclerosis is disease modifying: Yes	10
Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease	10
T1-based stratification of paramagnetic rim lesions in multiple sclerosis: Evidence of microstructural heterogeneity and clinical implications	10
Sleep-disordered breathing and neurocognitive function in multiple sclerosis: Differential associations across cognitive domains	10
Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome	10
Anaphylaxis and glatiramer acetate	9
Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–associated disease	9
Communication deficits in multiple sclerosis: Interactions with cognitive dysfunction and their impact on employment status	9
The characteristics and influencing factors of paramagnetic rim lesions in Chinese MS patients: A 7T MRI study	9
Cladribine: A useful treatment option in multiple sclerosis patients with autoimmune comorbidities	9
A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial	9
Treating comorbidities in MS is disease modifying: Commentary	9
Depression is a core symptom of multiple sclerosis: No	9
Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study	9
Seizure history and cognitive dysfunction in people with multiple sclerosis	9
How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder	9
Should autologous HSCT be a first-line option in highly active MS? No	9
Toward a holistic approach to multiple sclerosis: The role of social determinants of health	9
Generic MS medications: Reducing costs without compromising safety	9
Longitudinally extensive posterolateral myelitis revealing invasive CNS aspergillosis in an immunocompetent patient	9
Relapsing tumefactive demyelination: time to recognize a distinct demyelinating condition?	9
Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography	9
Phonemic processing is below expectations and linked to word-finding difficulty in multiple sclerosis	9
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis	9
Event-related potentials and behavioural correlates of cognitive functions in MS: An EEG study during symbol digit modalities test	9
Facial pain in MS: When to think of trigeminal autonomic cephalalgia	9
Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss	9
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS	9
Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study	8
The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now	8
Trends in central nervous system-active polypharmacy among people with multiple sclerosis	8
Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?	8
Blended versus face-to-face cognitive behavioural therapy for severe fatigue in patients with multiple sclerosis: A non-inferiority RCT	8
Navigating pregnancy in women with NMOSD in the monoclonal antibody era	8
Abstracts presented at the 10th Annual Meeting International MS Cognition Society (IMSCOGS), 2-3 September 2024, Bern, Switzerland	8
Brain and cervical spinal cord MRI correlates of sensorimotor impairment in patients with multiple sclerosis	8
Committees	8
Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years	8
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients	8
Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? Commentary	8
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis	8
Hypnosis and mindfulness audio recordings for reducing fatigue in individuals with multiple sclerosis: A randomized controlled study	8
Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders	8
Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case–control study	8
Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis	8
Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study	8
Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis	8
Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary	8
ACTRIMS Forum 2026 - Poster Presentations	8
Rectifying global inequities in neuromyelitis optica diagnosis and treatment	8
Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot walk and a patient-reported outcome measure	8
Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse	8
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial	8
Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a young woman under long-term B-cell depletion with ocrelizumab: A case report	8
Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs	8
Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis	8
Multiple sclerosis can be diagnosed solely with dissemination in space: Yes	8
Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas	8
Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination	8
A case of neuromyelitis optica spectrum disorder complicated with aquaporin-4-antibody-associated organizing pneumonia	7
Tumefactive demyelinating lesion during B-cell depletion therapy by ofatumumab	7
The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review	7
Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discont	7
Meaningful cognitive change for the Minimal Assessment of Cognitive Function in Multiple Sclerosis	7
Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system	7
An interdisciplinary approach is necessary in the treatment of cognitive decline in multiple sclerosis: Yes	7
HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis	7
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial	7
Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs	7
Exploring the relationship between polycystic ovarian syndrome, testosterone, and multiple sclerosis in women: A nationwide cohort study and genome-wide cross-trait analysis	7
Artificial intelligence will change MS care within the next 10 years: Commentary	7
Clinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod	7